Unprecedented PRESERVE IVC Filter Study Unites Surgeons, Interventionalists, Manufacturers, And The FDA
An unprecedented clinical trial called PRESERVE is bringing together the Society of Interventional Radiology, the Society for Vascular Surgery, major manufacturers of inferior vena cava filters, and the FDA to answer questions about how the filter might best fit into modern medicine.
You may also be interested in...
A nationwide observational study found that adjunctive inferior vena cava filter placement in patients undergoing catheter-directed thrombolysis does not reduce in-hospital mortality, but increases inpatient charges and length of stay. One-third of all patients undergoing catheter-directed thrombolysis receive IVC filters.
Serial medtech entrepreneurs Chas Taylor and Paul Gilson founded Novate Medical Ltd. to develop a bioconvertible inferior vena cava filter – it protects patients from pulmonary embolisms during a critical interval, then integrates into the vessel wall. There is no need to retrieve it, a benefit that goes far beyond the economics of avoiding a second procedure.
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.